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Multidrug-Resistant Pseudomonas aeruginosa 
Producing PER-1 Extended-Spectrum Serine-ß-
Lactamase and VIM-2 Metallo-ß-Lactamase
To the Editor: In Pseudomonas aeruginosa, secondary beta-
lactamases with extended substrate specificity can be 
responsible for acquired resistance to the most powerful 
antipseudomonal beta-lactams, such as expanded-spectrum 
cephalosporins and carbapenems (1). A number of these 
enzymes have been described, including extended-spectrum 
serine-beta-lactamases (ESBLs) of groups 2be and 2d (e.g., 
PER-1 and various OXA-type enzymes) (2,3) and metallo-
beta-lactamases of group 3 (e.g., IMP-1 and the recently 
described VIM-1 and VIM-2 enzymes) (2,4,5). The secondary 
ESBLs can degrade penicillins, expanded-spectrum cepha-
losporins, and monobactams (but not carbapenems) and are 
often susceptible to serine-beta-lactamase inhibitors (1-3). 
The secondary metallo-beta-lactamases, on the other hand, 
are notable for their carbapenemase activity and can 
degrade virtually all beta-lactams except monobactams, 
while being resistant to the currently available inhibitors 
(1,2,5,6).
On March 2000, a multidrug-resistant P. aeruginosa 
(isolate VA-182/00) was isolated in pure culture from a bron-
chial washing of a 58-year-old patient with multiple 
myeloma. The patient had been admitted 15 days earlier to 
the Varese University Hospital with a diagnosis of pneumo-
nia and had been treated with ciprofloxacin (0.5 g twice a 
day) plus piperacillin (2 g three times a day) for 12 days, and 
then with imipenem/cilastatin (0.5 g three times a day). No 
cultures of respiratory tract specimens were done earlier in 
hospitalization. Multiple myeloma had been diagnosed in 
1997, and the patient had been treated with multiple cycles 
of antiproliferative chemotherapy and had received autolo-
gous peripheral blood stem cell transplantation. According to 
clinical records, P. aeruginosa had not been isolated previ-
ously during this patient’s protracted illness. In vitro suscep-
tibility testing showed that the P. aeruginosa isolate was 
resistant to mezlocillin, ceftazidime, cefepime, aztreonam, 
imipenem, meropenem, gentamicin, tobramycin, netilmicyn 
(MICs, >128 µg/mL), amikacin (MIC, 64 µg/mL), ciprofloxa-
cin and levofloxacin (MICs, >32 µg/mL). Only piperacillin 
and piperacillin/tazobactam had MIC values slightly lower 
than the breakpoints for resistance (64 µg/mL and 48/4 µg/
mL, respectively), although–considering the normal MICs of 
piperacillin for susceptible P. aeruginosa (2-8 µg/mL)–it was 
evident that the isolate also had considerable biological 
resistance to these drugs. A double disk-diffusion test, car-
ried out with standard disks placed 20 mm apart (center-to-
center), showed synergy between clavulanate and aztre-
onam. The treatment was changed to piperacillin/tazobac-
tam (4 g four times a day), and a slow recovery ensued over a 
30-day period. The patient died 3 months later following a 
relapse of the underlying malignancy.
The unusually high carbapenem MICs exhibited by VA-
182/00 suggested production of a secondary metallo-beta-lac-
tamase, while the synergy between clavulanate and aztre-
onam suggested production of a secondary serine ESBL. A 
crude extract of that isolate, assayed spectrophotometrically 
(7), exhibited imipenem-hydrolyzing activity (94 nmol/min/
mg protein, inhibited by EDTA) as well as aztreonam-hydro-
lyzing activity (11 nmol/min/mg protein, resistant to EDTA). 
Analytic isoelectric focusing (IEF) of the extract, followed by 
development with the nitrocefin chromogenic substrate (7), 
showed three bands of beta-lactamase activity of pIs 5.4, 5.6, 
and 6.3, suggesting the presence of at least three different 
secondary enzymes. A colony-blot hybridization with probes 
for the blaIMP, blaVIM, and blaPER resistance genes (all of 
which have been previously detected in P. aeruginosa clinical 
isolates from the same hospital [8,9; Luzzaro F, unpub. 
data]) yielded positive results with both the blaVIM and the 
blaPER probes. Amplification of the resistance genes by poly-
merase chain reaction (PCR) with primers VIM/DIA-f (5'-
CAgATTgCCgATggTgTTTgg) and VIM/DIA-r (5'-AggTgggC-
CATTCAgCCAgA) for blaVIM genes (4,5) and BLAPER-f (5'-
gggACA(g/A)TC(g/C)(g/T)ATgAATgTCA) and BLAPER-r (5'-
ggg(C/T)(g/C)gCTTAgATAgTgCTgAT) for blaPER genes (9), 
yielded amplicons of the expected sizes (522 and 966 bp, 
respectively). Direct amplicon sequencing identified the two 
beta-lactamase determinants as blaVIM-2 (5) and blaPER-1 
(10), respectively, a finding consistent with the pIs 5.6 and 
5.4 beta-lactamase bands detected in IEF (3,5). Conjugative 
transfer of the resistance determinants to Escherichia coli 
proved unsuccessful. In a Southern blot analysis of total 
undigested DNA from VA-182/00, both the blaVIM and bla-
PER probes apparently hybridized to the chromosomal DNA 
band; no plasmid bands recognized by either probe were 
detected. A PCR experiment with primers OXA10-f (5'-ggAA-
CAAAgAgTTCTCTgCC) and OXA105-r (5'-TTAgCCAC-
CAATgATgCC(C/T)TC), suitable for amplification of blaOXA 
genes of the OXA-10 group, did not yield an amplicon of the 
expected size (719 bp), suggesting that the pI 6.3 beta-lacta-
mase band detected by IEF did not correspond to an enzyme 
of this group.
This is the first observation of a P. aeruginosa clinical 
isolate simultaneously producing a secondary PER-1 ESBL 
and a secondary metallo-beta-lactamase. The finding, 
observed in a hospital where both the resistance genes Letters
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(blaPER-1 and blaVIM-2) had been detected separately among 
clinical isolates, underscores the possibility of the emergence 
of new threatening combinations of resistance determinants 
among nosocomial pathogens. In fact, the recruitment of 
similar resistance determinants within a single P. aerugi-
nosa strain can determine a resistance phenotype to virtu-
ally all the available antipseudomonal beta-lactams, an 
occurrence that can be particularly dramatic when, as in the 
present case, resistance to beta-lactams is associated with 
resistance against aminoglycosides and fluoroquinolones. In 
this case, only piperacillin (which appears to be a relatively 
poor substrate for both enzymes [3,5]) retained moderate 
activity in vitro and, administered at high dosage in combi-
nation with tazobactam, was apparently effective in vivo. 
Should a similar resistance phenotype disseminate, it might 
have strategic implications for the development of new beta-
lactamase inhibitors and for selection of beta-lactam com-
pounds to associate wth inhibitors.
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Jamestown Canyon Virus: Seroprevalence in 
Connecticut
To the Editor: Jamestown Canyon virus (JCV), a member of 
the California serogroup, has a wide geographic distribution 
throughout much of temperate North America. It causes 
mild febrile illness and, rarely, aseptic meningitis or primary 
encephalitis (1). JCV has been isolated from mosquitoes each 
year that surveys have been done in Connecticut, and 28 
positive pools from 10 mosquito species were found during 
2000 (T. Andreadis, pers. commun.). In contrast, only 14 pos-
itive mosquito pools were found to contain West Nile virus 
(WNV), which has recently been introduced into Connecticut 
(2). JCV has been isolated from Aedes mosquitoes in Con-
necticut, and serologic evidence suggests it is widespread in 
deer (3,4). No recent seroprevalence surveys have been done 
in Connecticut, nor have any human cases of infection or dis-
ease due to JCV been documented. 
We report the results of two seroprevalence surveys 
done with standard indirect fluorescent assays (IFA) to 
detect immunoglobulin G antibodies to JCV. One survey 
examined 1,086 sera collected in 1990 from blood donors. 
The second survey examined 1,016 sera submitted to the 
Connecticut State Public Health Laboratory in 1995.
The IFA used JCV-infected baby hamster kidney cells 
(BHK-21). Infected and uninfected cell suspensions were air 
dried and fixed onto Teflon-coated, 12-well slides. Prepared 
slides were stored at -70°C. Sera were tested at a minimum 
dilution of 1:16. After incubation and washing of the fluores-
cein-conjugated counterstain, slides were dried and exam-
ined by fluorescent microscope (American Optical, Buffalo, 
NY). The positive human control serum was designated as 
the 4+ baseline with which the test sera were compared. 
Selected sera were tested by a serum dilution plaque reduc-
tion neutralization test (PRNT) assay with JCV, La Crosse 
virus, and trivittatus virus.
Of the 1,086 sera collected from blood donors in 1990, 
164 (15%) were positive by IFA at a minimum dilution of 
1:16. Because IFA screening procedures are known to have 
poor specificity, a subset of 39 IFA-positive and 5 IFA-nega-
tive sera was tested by PRNT. None of the IFA-negative sera 
were positive, while 26 (67%) of the 39 IFA-positive sera 
were positive for JCV antibodies. Extrapolating the PRNT 
results to the 164 IFA-positive sera yields an overall positiv-
ity rate of 10.1%. 
The second serosurvey, performed on 1,016 sera col-
lected in 1995 from apparently healthy patients requesting 
immune status testing to viruses such as Varicella zoster or 
measles, had 57 IFA-positive specimens. Extrapolating addi-